Profile photo

The Fellow on Call: The Heme/Onc Podcast

Oncology / Hematology

The Fellow on Call: The Heme/Onc Podcast is dedicated to bringing its listeners the fundamentals, core concepts, and important management approaches in the field of hematology and oncology, driven by the latest evidence and expert opinion. In each episode, the hosts provide answers to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to nurses, advanced practice providers, and practicing physicians.

Annual Hematology/Oncology Meetings Are Around the Corner

Hi friends,

Welcome to another edition of our monthly newsletter! For most of the United States, autumn is in the air with crisp mornings and shorter days. With this comes a time of great excitement–the holidays are around the corner, and we are in another season of big hematology/oncology meetings! We’re stoked about the latter. With meetings comes new data, allowing us to push the envelope further and continue to make improvements in the lives of our patients. 

In this month’s newsletter, we’re showcasing our diffuse large B cell lymphoma series that we just wrapped up and highlighting our new mini-series. In addition, we’re sharing stories that caught our attention in recent weeks. Let us know your thoughts on our picks! 

As always, we invite you to listen to our show, The Fellow on Call: The Heme/Onc Podcast. Episodes are uploaded weekly on Wednesdays to Apple Podcasts, Spotify, and Google Podcasts.

Cheers,

Ronak, Vivek, and Dan

Articles
  • Mashup Score: 0
    Combination therapies with immunotherapy and ADCs prolong overall survival in urothelial carcinoma - 7 month(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of ronak-h-mistrydo
      ronak-h-mistrydo

      Platinum-based therapy was our standard of care for locally advanced and metastatic bladder cancer for a long time. Promising data shared recently at ESMO 2023 is changing this paradigm. Highly awaited was the EV-302/KEYNOTE-A39 trial which showed that enfortumab vedotin with pembrolizumab almost doubled median progression-free survival and median overall survival compared with chemotherapy (cisplatin or carboplatin plus gemcitabine) at a median follow-up of 17.2 months in 886 patients with previously untreated, locally advanced or metastatic urothelial carcinoma! We will soon see this as our standard of care! 

  • Mashup Score: 176
    Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer | NEJM - 7 month(s) ago

    Original Article from The New England Journal of Medicine — Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

    Tweet Tweets with this article
    • Profile photo of RManochakian
      RManochakian

      🔥🚨@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO23. “Results of #AEGEAN trial of #Perioperative #Durvalumab (or #placebo) + neoadjuvant chemo in #Patients with respectable stage II-IIIB #NSCLC.” 👇🏼 https://t.co/rSYWYN4neL https://t.co/PtmqVBii4N

  • Mashup Score: 0
    Heme Consult Series: When anticoagulation fails - 7 month(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of ronak-h-mistrydo
      ronak-h-mistrydo

      We kicked off November with another "heme consult series" this time focusing on a question we get asked all the time: "Is this anticoagulation failure?" In this two-part series, we break down how we think about patients with new thrombotic events while on therapeutic anticoagulation. 

  • Mashup Score: 0
    How I treat posttransplant lymphoproliferative disorder - 7 month(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of ronak-h-mistrydo
      ronak-h-mistrydo

      If you're new to hematology or been doing this for a while but come across an interesting question, we highly recommend searching for the Blood Journal "How I Treat" articles. Written by world-experts, these are fantastic for a review on the disease in question, workup, and management. Highly recommend! This month, they just released how to approach "PTLD".